局限性分割强度调制放疗治疗头颈部癌症的毒性有限。
Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer.
机构信息
Cleveland Clinic Department of Radiation Oncology, Cleveland, OH, U.S.A.
Cleveland Clinic Department of Otolaryngology, Cleveland, OH, U.S.A.
出版信息
Anticancer Res. 2022 Apr;42(4):1845-1849. doi: 10.21873/anticanres.15660.
BACKGROUND/AIM: Hypofractionated radiation therapy is not commonly used in head and neck cancers (HNC) due to increased toxicity observed in historical cohorts. This study reviews our institutional experience using hypofractionated intensity modulated radiation therapy (H-IMRT) for HNC.
PATIENTS AND METHODS
A retrospective cohort study of 56 patients with HNC treated with H-IMRT with ≥50 Gy in 20 fractions was conducted. The primary outcomes were acute and late toxicity.
RESULTS
Two-year locoregional control was 87% and median overall survival was 46 months. There were no acute or late grade 4 or 5 toxicities. Acute grade 2 and 3 toxicity was seen in 79% (N=44) and 25% (N=14), respectively. Late grade 2 toxicity was seen in 9% (N=5). No patients required the placement of a feeding tube or tracheostomy.
CONCLUSION
H-IMRT for the definitive or post-operative treatment of HNC using ≥50 Gy in 20 fractions appears safe and well tolerated with modest toxicity.
背景/目的：由于在历史队列中观察到增加的毒性，在头颈部癌症（HNC）中不常使用分割放射治疗。本研究回顾了我们机构使用分割调强放射治疗（H-IMRT）治疗 HNC 的经验。
患者和方法
对 56 例接受 H-IMRT 治疗的 HNC 患者进行了回顾性队列研究，这些患者接受了≥50 Gy 的 20 个分数。主要结果是急性和迟发性毒性。
结果
两年局部区域控制率为 87%，中位总生存期为 46 个月。没有急性或迟发性 4 级或 5 级毒性。分别有 79%（N=44）和 25%（N=14）的患者出现急性 2 级和 3 级毒性。没有患者需要放置饲管或气管造口术。
结论
使用≥50 Gy 的 20 个分数的 H-IMRT 用于 HNC 的根治性或术后治疗似乎是安全且耐受良好的，毒性适度。
Zotero 插件